Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference
28 nov. 2023 16h05 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights
09 nov. 2023 16h05 HE
|
Adverum Biotechnologies, Inc.
- Announced preliminary aflibercept protein levels from the on-going Phase 2 LUNA trial, suggesting that both doses are within the therapeutically active range and consistent with aflibercept levels...
Adverum Biotechnologies Appoints C. David Nicholson, Ph.D. to its Board of Directors
06 nov. 2023 08h00 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023
04 nov. 2023 17h54 HE
|
Adverum Biotechnologies, Inc.
- Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of anatomical improvements and sustained reduction...
Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data from the LUNA Phase 2 Trial
26 sept. 2023 16h05 HE
|
Adverum Biotechnologies, Inc.
- Initial aflibercept protein levels in LUNA suggest Ixo-vec at both the 2E11 and 6E10 doses delivers aflibercept protein levels within the therapeutically active range - - Ixo-vec has been...
Adverum Biotechnologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
05 sept. 2023 16h05 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum Biotechnologies Appoints Andrew Ramelmeier, Ph.D. as Chief Technology Officer
21 août 2023 16h05 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Aug. 21, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum Biotechnologies to Participate in the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
14 août 2023 08h00 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...
Adverum Biotechnologies Completes Enrollment of Phase 2 LUNA Trial in Wet AMD and Reports Second Quarter 2023 Financial Results
10 août 2023 16h05 HE
|
Adverum Biotechnologies, Inc.
- LUNA 14-week data on aflibercept protein levels anticipated in the third quarter of 2023 and preliminary efficacy and safety data anticipated in the fourth quarter of 2023 - - Combined OPTIC...
Adverum Biotechnologies to Participate in the Jefferies Healthcare Conference
02 juin 2023 08h00 HE
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., June 02, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for...